Login to Access Video or Poster Abstract: MP64-01
Sources of Funding: None

Introduction

The CAPRA-S score uses pathologic data from radical prostatectomy to predict biochemical recurrence and mortality. Recently, external validation was performed using the American and European cohorts, however, it has not previously been validated in a large, multi-institutional Asian cohort. Thus, we independently validated CAPRA-S score in an independent multi-institutional Korean (K-CaP) database.

Methods

The study cohort comprised 3,274 patients treated with radical prostatectomy between March 2005 and December 2014. Prediction of biochemical recurrence was assessed by Kaplan-Meier analysis and the concordance index (c-index). Performance of CAPRA-S in predicting biochemical recurrence was assessed by calibration plots, and decision curve analysis.

Results

During the median follow-up duration of 43.0 months, biochemical recurrence developed in 697 patients (21.3%). When stratifying patients with a CAPRA-S of 0-2, 3-5, and 6-12 (defining low, intermediate and high risk group), 39.4%, 35.9%, and 24.7% of patients were in a CAPRA-S low, intermediate and high risk group, respectively. Also, estimated 5-year biochemical recurrence-free survival was 91.2%, 71.3% and 30.7%, respectively. The c-index of the CAPRA-S to predict biochemical recurrence was 0.782 (Fig. 1). The calibration plot at 5-year generally showed a good fit. Decision curve analysis revealed a greater net benefit (net increase in the proportion of patients appropriately identified for adjuvant treatment) of the CAPRA-S score for the threshold probabilities of treating all men or no men with adjuvant therapy (Fig. 2).

Conclusions

The CAPRA-S score was accurate when applied in a multi-institutional Korean database. It predicted biochemical recurrence after radical prostatectomy with a c-index of 0.782. The CAPRA-S score can be valuable that may aid in determining the need for adjuvant therapy.

Funding

None